NL-OMON39331已完成不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia - P03579
Merck Sharp & Dohme (MSD)0 个研究点目标入组 23 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •1. Children of either sex and of any race, 3 months to <18 years of age.;2. Subjects* parent or legally authorized representative must be willing to give written informed consent. Assent will be obtained from minors according to institutional practices.;3. Subjects must have documented or anticipated neutropenia (ANC <=500/mm3 [0.5 x 109/L]) expected to last for at least 7 days and only in the following clinical situations:
- •a. Acute leukemia (including new and relapse),
- •b. Myelodysplasia,
- •c. Severe aplastic anemia,
- •d. Autologous HSCT recipients,
- •e. High risk neuroblastoma,
- •f. Advanced stage non-Hodgkin*s lymphoma.
- •g. Recipients of allogeneic HSCT during the pre-engraftment period
- •(neutropenia period).;4. Male and female subjects of child-bearing potential must agree to use a medically accepted method of contraception throughout the study and for at least 30 days after stopping the medication, unless they are surgically or medically sterile or agree to abstain from sexual intercourse. Acceptable methods of contraception include 2 of the following:
- •a. Condoms (male or female) with spermicide,
- •b. Diaphragm or cervical cap (if acceptable according to local standard of care) with spermicide
- •c. Hormonal contraceptives or intrauterine device with spermicide (females).
排除标准
- •1. Subjects with proven IFI, as defined by the MSG/EORTC criteria (see Appendix 3), prior to study entry.;2. Subjects with Grade 3 or Grade 4 nausea and/or vomiting at Screening.;3. Subjects who have received POS within the past 10 days prior to Screening.;4. Subjects receiving prohibited drugs (please refer to Table3).;5. Subjects whose laboratory tests are outside normal limits, as follows:
- •a. AST or ALT >5 times the upper limit of normal (ULN)
- •b. Serum total bilirubin >2.5 x ULN
- •c. Calculated creatinine clearance <30 mL/min. Creatinine clearance will be calculated using the
- •following equation: Creatinine clearance = k*height (cm)/serum creatinine (mg/dL)
- •Where k = 0.45 for a full term baby less than 1 year old; 0.55 for children up to 12 years old; 0.55
- •for females between the ages of 13 and 21 years; 0.7 for males between the ages of 13 and 21
- •years.;6. Subjects with QTc prolongation:
- •a. Symptomatic QTc prolongation >450 msec (males) or >470 msec (females)
- •b. Any QTc prolongation of >500 msec;7. Subjects who are unable to receive study drug enterally.;8. Female subjects who are pregnant, intend to become pregnant during the course of the study, or are breast-feeding.;9. Subjects with a history of anaphylaxis attributed to the azole class of antifungal agents.;10. Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study, including receiving less than 7 days of POS.;11. Subjects who have already participated in this study or are participating in any Phase 1 clinical study or any study for a medication that has not yet received regulatory approval. Note: If the medication has received a regulatory approval for use in adults, then the medication would be considered to have received a regulatory approval for the purpose of this criterion. Any medication received by eligible subjects must also be aligned with the protocol guidance for prohibited medications (Table 3). ;12. Subjects who are part of the study staff personnel or family members of the study staff personnel.
研究者
相似试验
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaTreatment and prophylaxis of invasive fungal infectionsoropharyngeal candidiasis (OPC) and refractory OPC.MedDRA version: 17.1Level: PTClassification code 10050346Term: Oropharyngeal candidiasisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2007-004645-15-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.108
进行中（未招募）
不适用
A study to look at safety and acceptance of Posaconazole (study drug) given by mouth to children with a blood illness.Treatment and prophylaxis of invasive fungal infectionsMedDRA version: 14.1Level: LLTClassification code 10062642Term: Invasive mycosisSystem Organ Class: 100000004862EUCTR2007-004645-15-GRSchering Plough Research Institute, A Division of Schering Corporation108
进行中（未招募）
1 期
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia - NDtreatment and prophylaxis of invasive fungal infectionsoropharyngeal candidiasis (OPC) and refractory OPCMedDRA version: 9.1 Level: LLT Classification code 10050346 Term: Oropharyngeal candidiasisMedDRA version: 9.1 Level: HLGT Classification code 10017528 Term: Fungal infectious disordersEUCTR2007-004645-15-ITSchering Plough Research Institute142
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaEUCTR2007-004645-15-NLSchering Plough Research Institute, A Division of Schering Corporation108
未知
1 期
Phase 1 Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsJPRN-jRCT2080223015Bristol-Myers Squibb K.K.18